UB Paderborn / Katalog / Suche / in CDI

MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines

Biochemical and biophysical research communications, 2008-09, Vol.373 (4), p.607-612

2008

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 Trial of Nab-Paclitaxel Plus Carboplatin for Advanced NSCLC in Patients at Risk of Bleeding From VEGF Directed Therapies

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S45-S45

2014

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

The New England journal of medicine, 2018-05, Vol.378 (22), p.2093-2104

2018

Link zum Volltext

Verfügbarkeit prüfen

Comparative Effectiveness of Stereotactic Radiosurgery (SRS) Versus Whole Brain Radiation Therapy (WBRT) for Patients With Brain Metastases From Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2013-10, Vol.87 (2), p.S41-S41

2013

Link zum Volltext

Verfügbarkeit prüfen

Protein Arginine Methyltransferase-5 as a Novel Epigenetic Target in Lung Cancer

International journal of radiation oncology, biology, physics, 2013-10, Vol.87 (2), p.S656-S656

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2014-12, Vol.90 (5), p.1266-1267

2014

Link zum Volltext

Verfügbarkeit prüfen

557 PRMT5, a Novel Epigenetic Target in Lung Cancers

European journal of cancer (1990), 2012-11, Vol.48, p.171-171

2012

Link zum Volltext

Verfügbarkeit prüfen

EP16.03-009 Patterns of KEAP1 Genomic Co-alterations in Advanced Non-small Cell Lung Cancer Identified by Plasma-Based Genyotyping

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S589

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

Annals of oncology, 2014-02, Vol.25 (2), p.415-422

2014

Link zum Volltext

Verfügbarkeit prüfen

PCN121 ONCOLOGY MEDICATION UTILIZATION BASED ON FEDERAL DRUG ADMINISTRATION (FDA) LABELING, NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) CLINICAL PRACTICE GUIDELINE (GL) RECOMMENDATIONS, AND EVIDENCE FOR PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER (NSCLC): AN ANALYSIS FROM THE NCCN ONCOLOGY OUTCOMES DATABASE

Value in health, 2011, Vol.14 (3), p.A176-A177

2011

Link zum Volltext

Verfügbarkeit prüfen

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer

Annals of oncology, 2012-08, Vol.23 (8), p.2094-2102

2012

Link zum Volltext

Verfügbarkeit prüfen

78P Association between obesity, sex, and overall survival in patients with metastatic cancers treated with first- or second-line immune checkpoint inhibitors

Annals of oncology, 2022-09, Vol.33, p.S576

2022

Link zum Volltext

Verfügbarkeit prüfen

6MO Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up

Annals of oncology, 2022-04, Vol.33, p.S30-S31

2022

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy”: Annals of Oncology 2020; 31, suppl.4: S472 (abstr. 540P)

Annals of oncology, 2021-04, Vol.32 (4), p.577-577

2021

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy”

Annals of oncology, 2021-04, Vol.32 (4), p.577

2021

Link zum Volltext

Verfügbarkeit prüfen

P1.21-15 Prognostic Value of Change in Platelet Volume for Patients with Metastatic Non-small Cell Lung Cancer Treated with Pembrolizumab

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S240-S241

2023

Link zum Volltext

Verfügbarkeit prüfen

EP13.05-01 Early ctDNA Changes and Clinical Outcomes in Extensive Stage Small Cell Lung Cancer Patients on Nivolumab and Temozolomide

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S700-S701

2023

Link zum Volltext

Verfügbarkeit prüfen

EP14.05-004 Temozolomide and Atezolizumab as Second Line Treatment for Extensive Stage Small Cell Lung Cancer: A Randomized, Multi-Cohort Phase 2 Trial

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S544-S545

2022

Link zum Volltext

Verfügbarkeit prüfen

OA12.04 Efficacy of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer after Chemo-Immunotherapy: A Phase 2 Trial

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S32-S33

2022

Link zum Volltext

Verfügbarkeit prüfen

67P Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1

Annals of oncology, 2020-12, Vol.31, p.S1444-S1445

2020

Link zum Volltext

Verfügbarkeit prüfen

End of life resource utilization among patients receiving immunotherapy for advanced cancer

Annals of oncology, 2018-10, Vol.29, p.viii553-viii553

2018

Link zum Volltext

Verfügbarkeit prüfen

A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations

ESMO open, 2023-04, Vol.8 (2), p.101183-101183, Article 101183

2023

Link zum Volltext

Verfügbarkeit prüfen

540P Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy

Annals of oncology, 2020-09, Vol.31, p.S472-S473

2020

Link zum Volltext

Verfügbarkeit prüfen

Immune related adverse events across cancer types: Incidence, risk factors and survival

Annals of oncology, 2018-10, Vol.29, p.viii630-viii631

2018

Link zum Volltext

Verfügbarkeit prüfen

PV-0040: Patterns of care for the elderly with non-surgically treated stage III non-small cell lung cancer

Radiotherapy and oncology, 2018-04, Vol.127, p.S16-S16

2018

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines

Phase 2 Trial of Nab-Paclitaxel Plus Carboplatin for Advanced NSCLC in Patients at Risk of Bleeding From VEGF Directed Therapies

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Comparative Effectiveness of Stereotactic Radiosurgery (SRS) Versus Whole Brain Radiation Therapy (WBRT) for Patients With Brain Metastases From Non-Small Cell Lung Cancer (NSCLC)

Protein Arginine Methyltransferase-5 as a Novel Epigenetic Target in Lung Cancer

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer

557 PRMT5, a Novel Epigenetic Target in Lung Cancers

EP16.03-009 Patterns of KEAP1 Genomic Co-alterations in Advanced Non-small Cell Lung Cancer Identified by Plasma-Based Genyotyping

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer

78P Association between obesity, sex, and overall survival in patients with metastatic cancers treated with first- or second-line immune checkpoint inhibitors

6MO Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up

Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy”: Annals of Oncology 2020; 31, suppl.4: S472 (abstr. 540P)

Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy”

P1.21-15 Prognostic Value of Change in Platelet Volume for Patients with Metastatic Non-small Cell Lung Cancer Treated with Pembrolizumab

EP13.05-01 Early ctDNA Changes and Clinical Outcomes in Extensive Stage Small Cell Lung Cancer Patients on Nivolumab and Temozolomide

EP14.05-004 Temozolomide and Atezolizumab as Second Line Treatment for Extensive Stage Small Cell Lung Cancer: A Randomized, Multi-Cohort Phase 2 Trial

OA12.04 Efficacy of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer after Chemo-Immunotherapy: A Phase 2 Trial

67P Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1

End of life resource utilization among patients receiving immunotherapy for advanced cancer

A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations

540P Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy

Immune related adverse events across cancer types: Incidence, risk factors and survival

PV-0040: Patterns of care for the elderly with non-surgically treated stage III non-small cell lung cancer

Suchergebnisse filtern